Most Read Articles
3 years ago

WHO (2012) estimates that around 450 million people suffer from mental illness, with one–in–four families having at least one member with a mental illness at any point in time. According to the Malaysian Mental Health Association, mental illness is often misunderstood. For centuries, it has been seen as either possession by evil spirits, a moral weakness or punishment from a higher being. Those suffering from mental illness are commonly perceived to be restless, violent and unpredictable.

one year ago
Orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide were effective in achieving weight loss among overweight and obese adults at 52 weeks, a recent study found. Phentermine-topiramate and liraglutide were associated with the highest odds of achieving at least 5 percent weight loss.
Elvira Manzano, one year ago
The oral Janus kinase (JAK) inhibitor tofacitinib may be a promising therapeutic option for patients with ankylosing spondylitis (AS), according to an expert who presented results from a phase II study that was touted as the first to demonstrate the efficacy of a JAK inhibitor in AS. 
one year ago
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Tofacitinib shows therapeutic potential in ankylosing spondylitis

5 months ago

Twice-daily tofacitinib 5 and 10 mg may produce greater improvements in signs, symptoms and objective endpoints of active ankylosing spondylitis (AS) in adults compared with placebo, according to data from a phase II study.

In addition, the drug has showed a 12-week safety profile that is similar to that reported in other indications.

A total of 207 patients were randomly assigned to one of the following treatment arms: tofacitinib 2 mg (n=52; mean age 41.8 years; 65.4 percent male), 5 mg (n=52; mean age 41.2 years; 75 percent male), 10 mg (n=52; mean age 41.6 years; 73.1 percent male) and placebo (n=51; mean age 41.9 years; 62.7 percent male). Treatment was given for 12 weeks, with a 4-week washout period.

The Assessment of SpondyloArthritis International Society 20 percent improvement (ASAS20) response rate at week 12 was used as the primary efficacy endpoint. Secondary endpoints were objective measures of disease activity, patient-reported outcomes and MRI of sacroiliac joints and spine. Safety was also assessed.

In an Emax model, ASAS20 response rate was 67.4 percent in the 10 mg arm, 63 percent in the 5 mg arm, 56 percent in the 2 mg arm, and 40.1 percent in the placebo arm.

Supportive normal approximation analysis found that the ASAS20 response rate with tofacitinib 5 mg was significantly higher than with placebo (80.8 vs 41.2 percent; p<0.001). Response rates were also greater with tofacitinib 2 and 10 mg, although the differences were not significant (51.9 and 55.8 percent, respectively).

There were general improvements observed in the secondary endpoints in the tofacitinib 5 and 10 mg arms vs placebo. Objective endpoints, including MRI, particularly showed clear dose response.

In terms of safety, adverse events showed no significant intergroup differences, without any unexpected safety findings.

Changes seen in dose-dependent laboratory outcomes returned close to baseline by week 16.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
3 years ago

WHO (2012) estimates that around 450 million people suffer from mental illness, with one–in–four families having at least one member with a mental illness at any point in time. According to the Malaysian Mental Health Association, mental illness is often misunderstood. For centuries, it has been seen as either possession by evil spirits, a moral weakness or punishment from a higher being. Those suffering from mental illness are commonly perceived to be restless, violent and unpredictable.

one year ago
Orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide were effective in achieving weight loss among overweight and obese adults at 52 weeks, a recent study found. Phentermine-topiramate and liraglutide were associated with the highest odds of achieving at least 5 percent weight loss.
Elvira Manzano, one year ago
The oral Janus kinase (JAK) inhibitor tofacitinib may be a promising therapeutic option for patients with ankylosing spondylitis (AS), according to an expert who presented results from a phase II study that was touted as the first to demonstrate the efficacy of a JAK inhibitor in AS. 
one year ago
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.